Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase I/II study
This is the report of a randomized phase 1/2 study assessing the safety and efficacy of tremelimumab (T; anti-CTLA4) and durvalumab (D; anti-PD-L1) as monotherapies and in combination for patients with unresectable hepatocellular carcinoma, previously treated with (or refusing) sorafenib, including a novel regimen with a single, priming dose of tremelimumab. 332 patients were randomized to T300+D (N=75), durvalumab (N=104), tremelimumab (N=69), T75+D (N=84). Tolerability was acceptable, grade ³3 treatment-related adverse events occurred in 37.8%, 20.8%, 43.5%, 24.4%. Confirmed ORRs (95% CI) were 24.0% (14.9-35.3), 10.6% (5.4-18.1), 7.2% (2.4-16.1), 9.5% (4.2-17.9). Median (95% CI) overall survival was 18.7 (10.8-27.3), 13.6 (8.7-17.6), 15.1 (11.3-20.5), 11.3 (8.4-15.0) months, respectively. An early expansion of CD8+ lymphocytes was associated with response, with highest proliferating CD8+ lymphocyte levels in the T300+D arm. The T300+D regimen demonstrated the most encouraging benefit-risk profile and with D monotherapy is being evaluated versus sorafenib in the ongoing phase 3 HIMALAYA study.
(Kelley, R.K. et al. – J Clin Oncol, September 2021)
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.